Clonazepam Oral Solution Suppliers & Bulk Manufacturers
Available Forms: Oral Solution
Available Strengths: 2.5 mg/mL
Reference Brands: US: Klonopin®, Clonazepam ODT; EU: Rivotril®, Clonex®, Clonotril®, Clonarex®
Category:
Antipsychotropic Drugs
Clonazepam, a benzodiazepine, enhances GABA activity by binding to GABA-A receptors, promoting calming effects on the brain. It is primarily used to treat seizure disorders, panic disorder, and anxiety. The oral solution allows for flexible dosing, particularly useful in pediatric and elderly populations requiring precise titration.
Clonazepam Oral Solution is available in Oral Solution
and strengths such as 2.5 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Clonazepam Oral Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Clonazepam Oral Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
In the United States, Clonazepam oral solution is approved by the FDA for the treatment of seizure disorders and panic disorder. It is classified as a Schedule IV controlled substance due to its potential for dependence and misuse. The FDA mandates boxed warnings highlighting risks of abuse, dependence, and withdrawal.In the European Union, Clonazepam oral solutions, such as Rosemont’s 0.5 mg/5 ml and 2 mg/5 ml formulations, are authorized nationally for various epileptic conditions, including absence and myoclonic seizures. EU regulations require adherence to Good Manufacturing Practices (GMP) and comprehensive pharmacovigilance measures. For sourcing and regulatory support, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing